mate, like death and taxes a biotech putting positive spin on its results is an absolute certainty in life. As somebody pointed out they didn’t show any advantage for their main endpoint in the trial of change in viral load, so instead they ignored that rather essential point and chose to heavily promote their results for markers like cd163. nobody knows if they’re relevant and the blood markers were ‘secondary’ objectives but these companies figure that virtually no investor will have the technical expertise to challenge them. As a simple poster it wouldn’t have gone through a rigorous ‘peer review’ at the conference to get through. I don’t know what they did next post 2018 but if they didn’t then seek to get the “exciting” results published in a credible journal and they didn’t do anything more with their CD163 ‘epiphany’ then you need to ask why and yep I’d say the one or two who picked this apart back in 2018 were right.
BIT Price at posting:
1.9¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)